Clinical Trial Update: A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study assessing vedolizumab for steroid-refractory acute intestinal graft-versus-host disease in patients who underwent allogeneic hematopo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allogeneic Hematopoietic Stem Cell Transplantation-related Complications
• Graft-versus-host Disease

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Status: TERMINATED | Results posted: 2019-05-24